Excelya

Excelya

Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Excelya is a mid-sized, global contract research organization (CRO) headquartered in Paris, France, offering a full suite of clinical development services. The company differentiates itself through a flexible three-pillar business model (Full Service, FSP, Resourcing), deep therapeutic expertise, and a stated culture of 'Audacity, Care, and Energy.' With a network of experts across 25 countries and experience in over 550 clinical studies, Excelya positions itself as an agile partner capable of providing senior-level attention and tailored solutions for biotech and pharmaceutical clients.

Oncology & HematologyRare Disease & PediatricsInflammation & ImmunologyInfectious DiseasePain Treatment & CNS

Technology Platform

Integrated clinical development service platform organized into Centers of Excellence (Clinical Ops, Data Management, Stats & Programming, Pharmacovigilance, Medical Affairs, eTMF, Regulatory, QA). Leverages industry-standard EDC systems, 100% digital eTMF, and holds ISO 27001 certification for data security. Partnered with Veeva.

Funding History

1
Total raised:$25M
Series A$25M

Opportunities

Growing demand from small-to-mid-sized biotechs for flexible, expert CRO partners.
Expansion in complex, high-growth therapeutic areas like oncology and rare diseases.
Increasing need for Real-World Evidence (RWE) and late-phase study support.

Risk Factors

Intense competition from large global CROs and niche providers.
Operational risks related to clinical trial execution, regulatory compliance, and data security.
Dependence on attracting and retaining specialized talent in a competitive labor market.

Competitive Landscape

Operates in the highly competitive global CRO market, competing against large public players (e.g., IQVIA, ICON, LabCorp) and numerous mid-sized and specialty CROs. Differentiates through a flexible three-model service offering, mid-size agility providing senior attention, and deep therapeutic expertise in areas like oncology and rare diseases.